Boston Scientific
This article was originally published in The Gray Sheet
Executive Summary
Firm enrolls first patients in 532-patient TAXUS II trial evaluating paclitaxel-coated stents for reduction of in-stent restenosis. One in a series of studies under way, the trial will support CE mark approval, expected in 2002. A U.S. clinical trial, TAXUS IV, is slated to begin enrolling patients by year-end